Off-label use of orphan medicinal products: a Belgian qualitative study
Abstract Background Off-label use of (orphan) medicinal products for (rare) diseases is quite common but not underpinned by clinical studies to confirm efficacy and safety. No risk-analyses by regulatory agencies are carried out. The objective of this study was to map off-label use of orphan medicinal products in Belgium in terms of attitude towards off-label prescribing, factors influencing off-label prescribing, disclosure of information towards the patient, reporting of off-label use, risks and consequences. Most of the EMA authorized orphan drugs are fully reimbursed in Belgium under well-... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2016 |
Reihe/Periodikum: | Orphanet Journal of Rare Diseases, Vol 11, Iss 1, Pp 1-9 (2016) |
Verlag/Hrsg.: |
BMC
|
Schlagwörter: | Off-label use / Unlicensed use / Orphan medicinal products / Rare diseases / Safety / Efficacy / Medicine / R |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26527361 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1186/s13023-016-0507-y |